Get started

Shenzhen Pregene Biopharma Co., Ltd. (China)

Homepage: pregene.com
Alternate names: Shenzhen Pregene Biopharma Co., Ltd., 深圳普瑞金生物药业股份有限公司
ROR: 05dz0mr61
OpenAlex ID: I4405257574
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
2025 · Jia Xu, Lin Liu, et al. · The Lancet · 143
PDF
The Application of Nanobody in CAR-T Therapy
2021 · Chaolemeng Bao, Quanli Gao, et al. · Biomolecules · 112
PDF
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL
2022 · Lijun Zhao, Shuhong Li, et al. · Blood · 94
PDF
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
2026 · Ning An, Di Wang, et al. · Nature Medicine · 70
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
2021 · Lu Han, Ji-Shuai Zhang, et al. · Leukemia · 49
PDF
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis
2025 · Ziwei Hu, Shaozhe Cai, et al. · Annals of the Rheumatic Diseases · 46
PDF
Safety and Efficacy of CAR-T Cell Targeting BCMA in Patients with Multiple Myeloma Co-Infected with Chronic Hepatitis B Virus
2020 · Lu Han, Jian Zhou, et al. · Journal for ImmunoTherapy of Cancer · 44
PDF
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
2023 · Quan Ren, Yingling Zu, et al. · Experimental Hematology and Oncology · 39
PDF
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
2019 · Lu Han, Quanli Gao, et al. · Journal of Clinical Oncology · 28
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
2022 · Caixia Su, Yiwei Zhong, et al. · npj Vaccines · 25
PDF
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
2024 · Yingling Zu, Quan Ren, et al. · Experimental Hematology and Oncology · 16
PDF
A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies
2024 · Lijun Zhao, Shuhong Li, et al. · Protein & Cell · 12
The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.
2021 · Lu Han, Quanli Gao, et al. · Journal of Clinical Oncology · 11
Development and Evaluation of CART Targeting Bcma with Humanized Alpaca-Derived Single-Domain Antibody As Antigen Recognition Domain
2018 · Lu Han, Quanli Gao, et al. · Blood · 11
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
2021 · Lu Han, Jian Zhou, et al. · Cancer Biology and Medicine · 8
Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis
2025 · Shaozhe Cai, Yu Chen, et al. · The Lancet Rheumatology · 7
Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma
2024 · Jianmin Guo, Qiqi Wu, et al. · Frontiers in Immunology · 7
PDF
BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study
2025 · Jinhui Shu, Min Xu, et al. · Blood · 4
PDF
Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph+ B cell acute lymphoblastic leukemia
2022 · Lu Han, Ran Zhao, et al. · Frontiers in Immunology · 4
PDF
The clinical study of anti-bcma car-t with humanized single-domain antibody
2020 · L. Han, Q. Gao, et al. · Cytotherapy · 3
BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia
2026 · Jinhui Shu, Min Xu, et al. · Blood · 2
Anti-BCMA CAR T-cell for IgG4-related disease: is this necessary? – Authors' reply
2026 · Shaozhe Cai, Ziwei Hu, et al. · The Lancet Rheumatology · 1
Works count: 22
Citation count: 1,860
Year
Topic
Type